LivaNova (NasdaqGS:LIVN) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Speaker10Good day, ladies and gentlemen, and welcome to the LivaNova PLC fourth quarter and full year 2025 earnings conference call. My name is Emily, and I'll be coordinating your call today. After the presentation, you will have the opportunity to ask any questions, which you can do so by pressing star 1 on your telephone keypad. As a reminder, this conference call is being recorded. I would now like to introduce your host for to ...

Core Insights - The report from Zhonghang Securities highlights the ongoing integration of AI products and services in the healthcare sector, focusing on areas such as medical imaging, clinical decision support, precision medicine, health management, medical information technology, drug development, and medical robotics. AI is evolving from a "technical assistant" role to becoming a core driver of "value reshaping" and "efficiency revolution" in the medical industry, with its commercial value permeating from research to clinical, payment, and patient levels [1] International Developments - In the international arena, significant advancements are noted in AI medical imaging diagnostics and AI-assisted drug discovery. AI systems for abdominal CT multi-disease triage and fetal abnormal ultrasound imaging have received FDA approval, indicating a shift from single-disease assistance to comprehensive triage and decision support systems. Collaborations between pharmaceutical companies and AI tech firms are enhancing cancer early screening capabilities, potentially increasing cancer diagnosis rates and accessibility to treatment drugs. Additionally, AI imaging diagnostics for stroke have gained recognition at top academic conferences, reflecting the growing acceptance of AI technology in clinical and research communities [1] - In drug discovery, international pharmaceutical companies are partnering with AI tech firms to accelerate new drug development. The world's first fully AI-designed antibody drug, GB-0895, has entered Phase III clinical trials, marking a significant breakthrough from concept to clinical practice. Google has also launched two open-source AI models for medical applications, enhancing capabilities in multi-modal analysis and voice interaction [1] Domestic Developments - Domestically, the value of AI in early drug development is being clinically validated, with companies like InSilico Medicine receiving FDA approval for new drug applications via AI platforms. AI-assisted diagnosis is expanding into various medical scenarios, with recent approvals for AI software in cervical cell digital pathology and accelerated AI healthcare initiatives from leading in vitro diagnostic companies. The emergence of large AI models in China is also noteworthy, with local teams publishing evaluation standards in international journals, showcasing the competitive edge of Chinese medical AI models [2] - Significant advancements are being made in AI imaging, surgical robots, and brain-computer interfaces, with AI accelerating the development of medicine and drug research. Recent policies related to AI in healthcare are being actively discussed, focusing on the reliability and compliance of AI-assisted diagnosis and the use of medical data [2] Investment Opportunities - Key investment opportunities identified include: 1) AI drug development: companies like Crystal Technology, Hongbo Pharmaceutical, Chengdu XianDao, and InSilico Medicine 2) AI medical imaging and assisted diagnosis: companies such as United Imaging Healthcare and Wandong Medical 3) Medical information technology and smart hospitals: firms like Jiahe Meikang, Chuangye Huikang, Donghua Software, and Weining Health 4) Internet healthcare and health platforms: including JD Health, Alibaba Health, and Ping An Good Doctor 5) Precision medicine and AI-driven medical services: companies like Kingmed Diagnostics, Runda Medical, and Meinian Health 6) Technology/data platform enterprises: such as iFlytek Medical and Yidu Technology [4] AI Medical Core Themes - The core themes in AI healthcare investment revolve around addressing industry pain points. AI-assisted diagnosis enhances diagnostic efficiency and consistency, supporting grassroots healthcare with clear cost-reduction and efficiency benefits. In cancer early screening, companion diagnostics, and efficacy prediction, AI contributes to achieving precision medicine. The maturity of AI applications varies, with AI medical imaging evolving from single-disease assistance to multi-disease integration and comprehensive management. AI-assisted drug discovery is transitioning from early discovery to clinical validation, necessitating attention to platform technology validation and deep collaborations with top pharmaceutical companies [3] - The development of large medical AI models and multi-modal AI, capable of processing diverse medical data, is crucial. The focus should be on the accuracy of these models in specialized fields, their integration with existing hospital information systems, and their potential to build an ecosystem as foundational "medical intelligent agents" [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603108 证券简称：润达医疗 公告编号：临2026-016 上海润达医疗科技股份有限公司 股东及董高减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 大股东及董高持股的基本情况 截至本公告披露日：公司董事、高级管理人员刘辉持有上海润达医疗科技股份有限公司（以下简称"公 司"、"润达医疗"）股份共计31,528,771股，占公司总股本5.22%。公司股东朱文怡持有公司股份共计 28,839,409股，占公司总股本4.78%。 转债代码：113588 转债简称：润达转债 ● 减持计划的主要内容 公司股东朱文怡及刘辉拟在本公告之日起15个交易日后的三个月内通过大宗交易或集中竞价交易方式减 持股份。 ■ 股东后续减持公司股份将严格遵守相关法律法规执行。在本减持计划公告之日起至减持计划实施期间， 公司如发生派发红利、送红股、转增股本、增发新股或配股等除权、除息事项，上述减持股份数量将相 应进行调整。 ■ 上述减持主体存在一致行动 ...

"李超人"、"老狐狸"、"香港首富"......能把这几个标签串联在一起的，怕是只有李嘉诚了吧。 这位商界巨擘曾是华人富豪的象征，年少自潮州南下香港，14岁辍学谋生，从塑胶花起步，逐步进军地 产、港口、零售、能源、电讯等数十个领域，财富迅速积累，家族产业遍及全球50余国，打造了一个国 际化的大型企业集团。 2018年，时年90岁的李嘉诚宣布退休，退居幕后担任资深顾问，过上了极为低调的晚年生活，鲜少露 面，逐渐淡出公众视野。 李嘉诚也很无奈，自己的商业帝国早已遍布全球，曾在欧洲商圈叱咤风云，没想到居然在中美洲"翻了 船"，遇到个"不讲理"的。 前不久，李嘉诚以451亿美元身家（约3517.8亿港元）蝉联香港首富。 就在众人感慨其宝刀未老时，李嘉诚重仓海外的港口事业却迎来"致命危机"。 在这样完全不对等的博弈中，他已无法再继续长袖善舞。 此前多次沟通反对无果，这次钟爱于投资海外的李嘉诚怕是真的要"栽了"。 已近期颐之年的李嘉诚，不得不出面，再次为家族前程劳心费力。 巴拿马政府强行接管香港长江和记集团营运的两个港口，同时禁止巴拿马港口公司代表进入这两个货柜 码头。而巴拿马港口公司正是长江和记间接持有之附属公司。 0 ...

Core Viewpoint - The article highlights the vibrant atmosphere in Chongqing as various industries resume operations after the Spring Festival, showcasing a strong commitment to growth and development in the new year [1][4]. Group 1: Industry Activity - On the first day back to work after the Spring Festival, various sectors in Chongqing are actively engaged in their operations, aiming for a strong start to the year [1]. - Companies like BaLu Technology focus on industrial software products, planning to expand their market presence outside Chongqing by 2026 [1]. - JuCe Health Technology Co., a medical tech firm, emphasizes home health monitoring and aims to make health management more accessible through innovative technologies [2]. Group 2: Business Performance - JuCe's production department reports a strong order backlog, with expectations of achieving an annual output value of 30 million yuan, reflecting a year-on-year growth of over 30% [4]. - The service teams are actively visiting businesses to understand their needs better, enhancing service efficiency and responsiveness [4]. Group 3: Cultural and Community Engagement - The reopening day featured traditional lion dance performances, symbolizing prosperity and good fortune for the businesses in the area [6]. - Local businesses, including hotels, are preparing to welcome customers with improved services and cleanliness, reflecting a commitment to safety and quality [7].

2026年生命科学行业展望 2026年生命科学行业展望 | 市场情绪因受访者所处区域和细分领域而异 市场情绪因受访者所处区域和细分领域而异 生命科学行业高管认为企业财务前景比较乐观，但需在复杂国际局势中增强韧性 2026年生命科学行业展望 生命科学行业的"无国界属性"或许日益凸显，但行业信心却出现分化。德勤《2026 年生命科学行业展望调研》显示，超过75% 的生物制药与医疗科技行业受访高管对企业 来年的财务前景抱有信心；但仅41% 的受访者对全球经济的健康程度持乐观态度。 未来一年，能够在"把握全球发展趋势"与"增强本地运营韧性"间实现平衡的企业或 将脱颖而出――既需大胆布局人工智能与新兴技术，也需具备灵活应对监管及经济变化 的能力。 为深入了解行业关注重点，德勤美国健康解决方案中心联合德勤全球，于2025 年8-9 月开展了第四次年度生命科学行业展望调研。本次调研覆盖280 位来自美国、欧洲（法 国、德国、瑞士、英国）及亚洲（中国、日本）的生物制药与医疗科技企业高管；同时 结合对多位行业领袖的深度访谈，进一步丰富了调研洞察。（详见《调研方法》部分） 整体而言，多数受访行业领导者认为，2026 年的实质性转 ...

据港交所文件：杭州糖吉医疗科技股份有限公司-B向港交所提交上市申请书。 来源：滚动播报 ...

证券之星消息，根据天眼查APP于2月10日公布的信息整理，安晴人工智能科技（湖州）有限公司天使 轮融资，融资额未披露，参与投资的机构包括浙商创投。 公司专注于人工智能技术开发及医疗科技融合应用，致力于构建'AI+医疗'技术生态。本轮融资将用于 加速核心算法研发、医疗合规认证及临床场景落地。 数据来源：天眼查APP 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

转自：中国科学报 上海交通大学人工智能学院教授张娅、副教授谢伟迪与医学院附属新华医院教授孙锟、教授余永国领衔 多方科研力量，针对罕见病"确诊难、漏诊率高"的全球性难题，提出了全球首个智能体式罕见病循证推 理诊断系统DeepRare。2月19日，相关研究成果发表于《自然》。 同期，《自然》邀请西澳大利亚大学副教授蒂莫·拉斯曼（Timo Lassmann）撰写专文评论（News & views）。文中指出，DeepRare 最重要的两点意义包括：打破人工智能（AI）临床诊断的"黑盒"，以完 整可信的推理过程赢得了医学界的信任；构建了"实时知识检索+自我反思迭代"的AI通用技术，为需要 复杂逻辑推理的领域提供了共通的"解题思路"。 转化医学领域的领军人物、美国斯克里普斯研究转化研究所所长埃里克·托波尔（Eric Topol）也第一时 间推荐，将DeepRare视作Agentic AI在医学领域的优秀范例。 从"黑盒"到"白盒" 据了解，全球已有超过3.5亿人受到罕见病影响，病种超过7000种，约80%为遗传性疾病。大多数患者 在确诊前需经历5年以上的延迟、7次以上就诊、3次以上误诊，平均误诊率高达40%-50%，给 ...

论文数据显示，DeepRare的诊断效能实现颠覆性突破。仅依靠患者临床表型、不借助基因数据时，其首 位诊断准确率达57.18%，较该领域国际最佳模型提升23.79个百分点，彻底改变"不测基因难确诊"的困 境。在回顾性人机对比中，其诊断召回率超越拥有十年临床经验的罕见病专科医生，成为首个在该指标 上优于人类医生的罕见病诊断方法。引入基因数据后，其复杂病例综合首位准确率突破70.6%，显著优 于国际通用工具Exomiser(53.2%)，系统推理报告更获得95.4%的临床专家认可。 图 中新网上海新闻2月19日电（记者 许婧）北京时间2月19日凌晨，国际顶级学术期刊《自然》(Nature)在 线发表上海交通大学人工智能学院与医学院附属新华医院联合团队的重磅成果，同期《自然》 News&views版块配发专文评论，评价该成果在AI罕见病诊断领域的突破性意义。 该研究由上海交大张娅教授、谢伟迪副教授与新华医院孙锟教授、余永国教授领衔，针对罕见病"确诊 难、漏诊率高"的全球性难题，研发出全球首个智能体式罕见病循证推理诊断系统DeepRare。该系统采 用创新"中枢-分身"架构，在三大维度实现对传统医学AI的代际超越。 ...